Recent NRBO News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/21/2024 08:02:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:08:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:01:18 PM
- NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:30:30 PM
- NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/13/2024 12:01:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/07/2024 12:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 12:30:17 PM
- NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 08/06/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 12:30:18 PM
- NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 • PR Newswire (US) • 07/30/2024 12:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/25/2024 04:15:06 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/24/2024 09:11:14 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/18/2024 12:21:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 12:30:27 PM
- NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 06/26/2024 01:06:00 PM
- NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 06/25/2024 09:08:00 PM
- NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 06/24/2024 12:01:00 PM
- NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models • PR Newswire (US) • 06/22/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 11:26:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:06:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:30:16 PM
- NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone • PR Newswire (US) • 05/22/2024 12:01:00 PM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM